GEORGETOWN, Texas--(BUSINESS WIRE)--Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of novel targeted toxin-based therapeutics for oncology, announced today that it has been selected for two poster presentations at the 101st American Association for Cancer Research (AACR) annual meeting in Washington D.C. during April 19-21, 2010. In a presentation, entitled “Novel toxin library for the discovery of oncology therapeutics,” the company will report the development of a unique targeted toxin-based therapeutic drug development platform. Researchers at Molecular Templates have created a vast library of toxin-based molecules, each with specifically directed cell-kill activity. This proprietary library is currently being used by the company to rapidly screen against a series of targets and disease-states to identify and advance novel targeted oncology therapies toward the clinic. In a separate poster presentation, researchers will present preclinical proof-of-concept of the toxin-based platform demonstrating the identification of a pre-clinical candidate for melanoma, MTI-SAM3, using an etiology-based screen in which the target was not a priori identified.
